Global Medical REIT, Inc. (GMRE)

In the past six months, Global Medical REIT, Inc.'s stock experienced a share price decline of 11.09% between January 2, 2025, and December 31, 2025. The 52-week high was $45.65 on March 3, 2025, and the 52-week low was $29.05 on November 5, 2025. On September 24, 2025, GMRE's stock price increased by over 10%, rising from $7.53 to $36.07. Insider activity in November 2025 included CEO Mark Okey Decker, Jr. purchasing 10,000 shares for a total of $325,800.00. Analyst ratings have varied, with downgrades from Wall Street Zen and Robert W. Baird, and upgrades from Citigroup and Zacks Research. As of January 11, 2026, brokerages have given GMRE a consensus recommendation of "Moderate Buy" with an average 12-month price target of $41.50.

Demand for Global Medical REIT, Inc.'s products and services is characterized as vital and sustainable, bolstered by favorable demographic trends and a shift in healthcare delivery towards local markets and specialized facilities, suggesting relatively stable demand rather than significant seasonality.

Global Medical REIT, Inc. (GMRE) is an internally managed real estate investment trust (REIT) focused on acquiring licensed, state-of-the-art, purpose-built healthcare facilities, which it leases to physician groups and healthcare systems. GMRE operates within the Specialized REITs sector and aims to deliver attractive, risk-adjusted returns through sustainable rental income, reliable dividends, and potential long-term capital appreciation.

Global Medical REIT, Inc.'s portfolio of healthcare facilities is strategically located across various states in the United States, including Texas, Florida, Ohio, Oklahoma, Pennsylvania, Arizona, Illinois, and Michigan.

Global Medical REIT, Inc. has generally maintained a positive brand reputation among analysts, receiving a consensus rating of "Moderate Buy" from seven brokerages. The average 12-month price target from these analysts is $41.50, with a high forecast of $50.00 and a low of $35.00, suggesting a positive outlook for the stock. The company's objective to provide attractive risk-adjusted returns and reliable dividends contributes to its reputation. While there haven't been explicit negative events severely impacting its reputation, the stock has underperformed both the US Health Care REITs industry and the broader US market over the past year.

Global Medical REIT, Inc. has a significant portion of its stock held by institutional shareholders, accounting for 68.92% of ownership, while insiders hold 385.82% and retail investors hold 0.00%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., State Street Corp, Geode Capital Management, Llc, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., Invesco Ltd., Alyeska Investment Group, L.P., Bank of New York Mellon Corp, Prudential Financial Inc, and Hotchkis & Wiley Capital Management Llc. The largest individual shareholder is Yanping Huang, who owns 14.31 million shares, representing 106.77% of the company.